Of note, the related BET inhibitor I-BET76224 is currently in clinical trials for NUT midline carcinoma, an aggressive epithelial carcinoma characterized by genomic rearrangement of BRD4 or BRD3 (ClinicalTrials.gov identifier: NCT01587703). Here, BRD4 is linked to nut midline carcinoma.